⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PFE News
Pfizer Inc.
Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes
globenewswire.com
PFE
LLY
MGNX
LGND
Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million
globenewswire.com
PFE
MRK
ABBV
AZN
SNY
Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030
globenewswire.com
PFE
MRK
ABBV
NVS
SNY
BMY
AZN
GSK
Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate
globenewswire.com
PFE
MRK
NVS
PRPH
Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis
globenewswire.com
PFE
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect
accessnewswire.com
VALN
PFE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
accessnewswire.com
VALN
PFE
Институт Critical Path Institute запускает программу One to Millions, чтобы изменить будущее персонализированной медицины в глобальном масштабе USA - Pусский USA - English USA - English USA - Français USA - slovenčina USA - Polski USA - español USA -
prnewswire.com
BMY
MRK
PFE
GILD
REGN
AZN
NVS
BIIB
ALKS
CRIS
EDIT
NTLA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
accessnewswire.com
VALN
PFE
Preliminary Results for the Year Ended 31 December 2025
globenewswire.com
BDRX
PFE